Skip to main content
Premium Trial:

Request an Annual Quote

KeyGene, Floragenex Settle Patent Dispute, Enter Licensing Deal

NEW YORK (GenomeWeb News) – KeyGene and Floragenex today said that they have agreed to end a legal dispute and have entered into a licensing agreement covering sequence-based genotyping technology.

KeyGene had filed the patent infringement suit against Floragenex last year in the US District Court for the District of Orgeon.

Under terms of the agreement announced today, Oregon-based Floragenex has taken a non-exclusive, royalty-bearing license to KeyGene's intellectual property. The deal enables it to continue applying its Restriction-site Associated DNA method in specified fields including non-commercial and academic research in all species.

Further terms of the agreement ere not disclosed.

"Floragenex and KeyGene share share the belief that genotyping with next-generation sequencing technology holds tremendous promise for applications in all species," Floragenex President Rick Nipper said in a statement. "The power of sequencing platforms today and in the future open up new markets and opportunities for RADseq and similar applications as substitutes for fixed content genotyping arrays."

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.